SDHB and neoplasm: Determining the somatic and germline alterations underlining tumor development is also critical for appropriate targeted therapy selections, as SDH-deficient and NF1-related tumors are known to respond poorly to traditional imatinib therapy and differentiating the different genetic alterations in KIT/PDGFRA-wildtype GISTs can guide treatment choices3,4.